Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Short-term Investments (2023 - 2025)

Historic Short-term Investments for Collegium Pharmaceutical (COLL) over the last 3 years, with Q3 2025 value amounting to $135.8 million.

  • Collegium Pharmaceutical's Short-term Investments rose 6761.98% to $135.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $135.8 million, marking a year-over-year increase of 6761.98%. This contributed to the annual value of $92.2 million for FY2024, which is 2876.64% up from last year.
  • According to the latest figures from Q3 2025, Collegium Pharmaceutical's Short-term Investments is $135.8 million, which was up 6761.98% from $104.8 million recorded in Q2 2025.
  • Collegium Pharmaceutical's 5-year Short-term Investments high stood at $135.8 million for Q3 2025, and its period low was $41.7 million during Q2 2023.
  • Its 3-year average for Short-term Investments is $86.3 million, with a median of $90.8 million in 2024.
  • As far as peak fluctuations go, Collegium Pharmaceutical's Short-term Investments skyrocketed by 13666.02% in 2024, and later surged by 614.56% in 2025.
  • Over the past 3 years, Collegium Pharmaceutical's Short-term Investments (Quarter) stood at $71.6 million in 2023, then rose by 28.77% to $92.2 million in 2024, then surged by 47.26% to $135.8 million in 2025.
  • Its Short-term Investments was $135.8 million in Q3 2025, compared to $104.8 million in Q2 2025 and $101.6 million in Q1 2025.